Quick Buzz Feed
Serve Robotics is already expanding beyond just sidewalk delivery robots.
Serve Robotics, a spinoff from Uber Technologies' robotics division, Postmates X, is rapidly expanding its last-mile delivery operations across various U.S. markets, including Los Angeles, Atlanta, Dallas-Fort Worth, Miami, Fort Lauderdale, Chicago, and Alexandria, Virginia, with over 2,000 robots currently deployed. The company's autonomous robots are equipped with advanced sensors and machine learning to safely navigate urban environments, aiming to reduce delivery costs and emissions. Significantly, Serve Robotics is now extending its AI technology beyond traditional sidewalk deliveries, indicating a strategic move into broader market segments through a recent acquisition.
Despite being covered by a limited number of analysts, Serve Robotics has garnered positive consensus ratings, with one prominent analyst, Michael Latimore of Northland Capital Market, identifying it as a top pick for 2026 with a price target that suggests a potential doubling from recent levels. This bullish outlook does not yet fully account for Serve's latest acquisition of Diligent Robotics, a company specializing in AI-powered robot assistants for the healthcare sector. This transaction signifies Serve's initial foray into indoor autonomous environments, particularly impactful settings like hospitals. Diligent's 'Moxi' robots are already operational in over 25 U.S. hospital facilities and utilize Nvidia's Jetson embedded robotics platform. A report by MarketsAndMarkets projects the global humanoid robot market to experience a robust compound annual growth rate of 39.2%, growing from $2.92 billion in 2025 to $15.26 billion by 2030, driven by increasing applications in personal assistance, caregiving, healthcare, manufacturing, retail, and logistics. This substantial market expansion, especially into humanoid robotics, suggests that Serve Robotics' potential may be underestimated by current investors, potentially making its stock an opportune investment after its recent drop post-acquisition announcement.